Create personalized user journeys with Omnichannel Marketing as a Service.
Empower your marketing operations with AI and Data.
Adopt a future-proof holistic approach to content strategy.
Leverage a suite of professional services for pharma and life sciences.
Develop and enable adaptable pharma and life sciences marketing content.
Enable format-free marketing with content management platform.
The innovation-powered content management platform to produce and distribute high quality digital content
Discover our story, values, and how we're making a positive impact
Explore the heart of our organization and meet the visionary minds
The Viseven team is about respect, diversity, comfortable working conditions, and equal opportunities for everyone. We explore, evolve, and adapt – together.
A groundbreaking drug is ready to change lives, but regulatory hurdles, soaring R&D costs, and pricing pressures stand in the way of its success. For the pharmaceutical industry, this scenario is the reality of 2025.
With a global talent shortage, aging populations driving up healthcare demands, and supply chains still recovering from recent and ongoing crises, the challenges are mounting up for the pharma industry. Add the rapid adoption of artificial intelligence and advanced therapies, and you’ll see the industry facing a pivotal moment of both struggle and opportunity.
In this article, we’ll unpack the most pressing issues shaping pharma in 2025 and explore how companies can navigate this complex landscape. Let’s dive in.
The challenges facing the pharmaceutical market are anything but simple — they’re the result of a tangled web of issues that seem to snowball. Regulatory hurdles, like slow approval timelines and conflicting evidence requirements, create roadblocks that delay medicines from reaching patients. Add to this the rising costs of raw materials, labor, and transportation, and it becomes clear why pharmaceutical companies are struggling to balance innovation with affordability. And let’s not forget healthcare systems operate on tight budgets, which can make implementing new therapies an uphill battle.
Operational challenges further exacerbate the situation. Talent shortages, particularly in STEM and digital roles, threaten to slow progress in research and innovation. At the same time, pharmaceutical supply chain vulnerabilities exposed by global disruptions, such as the COVID-19 pandemic, continue to disrupt production and distribution. Pharma companies also face difficulties integrating advanced technologies like AI and personalized medicine into their operations, while navigating regulatory compliance.
Combined with health system infrastructure gaps and strategic decision-making errors, these factors create a complex environment that demands strategic collaboration and innovative solutions to ensure a sustainable future for the industry.
Pharmaceutical industry obstacles often repeat year to year. Regulations that continuously change, rising costs, an aging population, and tech advancements uncover the industry’s resistance and fear of change. Still, it’s critical to discuss the biggest challenges so that you are aware and can build effective strategies to counter them.
Regulatory hurdles are some of the most significant challenges pharmaceutical companies face today. Every country has its own rules and standards for drug approvals. The U.S. Food and Drug Administration (FDA) operates differently from the European Medicines Agency (EMA), and emerging markets often add another layer of complexity. For pharmaceutical companies trying to bring a drug to market globally, it’s like navigating a maze where the rules keep changing. Add to that the constant evolution of regulations (case in point, the U.S. Inflation Reduction Act), and you’ve got a moving target that demands constant adaptation.
The drug approval process doesn’t make things any easier. It’s not just lengthy — it’s expensive. With clinical trials stretching over years and costing billions, the stakes are incredibly high. And the kicker is that there’s no guarantee of success. That’s a huge risk for companies trying to innovate while keeping costs under control.
Now, let’s talk about marketing — because regulatory challenges don’t stop once the drug is approved. Many countries, for example, ban direct-to-consumer advertising altogether. Even in places like the U.S. and New Zealand, where it’s allowed, the rules are strict.
Then there’s the issue of transparency. Companies are required to disclose detailed information — everything from clinical trial results to financial relationships with healthcare providers. While transparency is critical for building trust, it often limits how creatively companies can communicate with their audiences. This makes overcoming the challenges in pharma marketing a balancing act between staying compliant and effectively engaging patients and healthcare professionals.
The pharmaceutical industry is grappling with a significant talent shortage, particularly in STEM and digital roles, as demand for specialized expertise outpaces supply. This gap is further widened by an aging workforce, with many experienced professionals retiring and leaving critical positions unfilled.
Advancements in technology and the shift towards digital and personalized medicine have only heightened the need for skilled talent. At the same time, changing workforce expectations, like the desire for flexible working arrangements, add another layer of complexity for companies trying to attract and retain top talent. Without addressing these challenges, the pharmaceutical industry risks stalling innovation and falling behind in a rapidly evolving landscape.
Intellectual property challenges are a constant juggling act for pharmaceutical companies. On one hand, patents are crucial — they protect groundbreaking innovations and help recoup the massive investments poured into R&D. But there’s a flip side: strict intellectual property protections can limit access to affordable medicines. When patents expire, the competition from generics heats up, shrinking market share and profits for the original innovators. And let’s not forget the growing issue of counterfeit drugs, which not only put patients at risk but also harm the reputation of trusted brands.
The intellectual property landscape adds to the complexity, with new technologies like artificial intelligence raising questions about ownership and enforcement varying widely across markets like India and China.
Add to this public scrutiny over profit-driven priorities, and it’s clear that pharma companies are under pressure to find a balance between protecting their innovations and ensuring fair access to treatments.
When we go to a hospital or visit a doctor, we expect the drugs we need to be there waiting for us. It’s hard for us to imagine that a hospital might tell a patient that their treatment needs to be delayed because of a medicine shortage, or they are simply unavailable because of logistics challenges in the pharmaceutical industry. Unfortunately, this is the reality we are living in because of pharma supply chain challenges.
It should be noted that these problems existed even before the pandemic, and the economic challenges for the pharmaceutical industry made shortages even more acute.
When everything is running smoothly, the economics of the global supply chain can bring in a lot of profit, but when it fails, the human cost is enormous. In fact, some basic essential medications that are used every day in emergency rooms and outpatient clinics have been in short supply.
Figuring out how to store and manage data securely is another big hurdle. With cyber threats on the rise, pharma companies are becoming prime targets for identity theft and increasingly sophisticated attack methods. The push for digitization has only added to this challenge — more valuable data stored online means a bigger bullseye for cybercriminals.
It doesn’t stop there. Pharmaceutical companies rely on countless devices to collect sensitive health and patient data, often connected through tools like big data analytics and the Internet of Things (IoT). While these technologies bring incredible benefits, they also amplify risks, making it essential for companies to prioritize security and privacy right from the start.
In such a complex environment, how can pharma marketers effectively engage with healthcare professionals? Limited targeting options and the intricate healthcare landscape make this task particularly difficult. Most targeting capabilities focus only on geography and specialization, whereas marketers require insights based on prescription behavior and formulary access. Adding to the obstacle, the healthcare market involves multiple stakeholders — providers, insurers, and patients — who all influence decision-making.
Reaching a critical mass of physicians to meet business goals is equally daunting. Fragmented outreach efforts often fail to engage HCPs meaningfully. Promotional content on company websites is often met with skepticism, while scientific journals may not always accommodate marketing messages, leaving marketers struggling to connect with healthcare professionals effectively.
Resistance to change is another one of the key challenges looming in the pharmaceutical industry. And it’s driven by various factors. Management often hesitates to make substantial operational changes, fearing disruptions and increased complexity. The highly regulated nature of the industry adds another layer of difficulty, as even minor changes require expensive revalidation processes. Additionally, manufacturing challenges lead some companies to rely on paper records, which can obscure errors and avoid scrutiny.
The financial and logistical burden of compliance frequently deters companies from adopting new solutions, even when they are clearly needed. Long-standing processes and deeply ingrained habits further contribute to this resistance, with employees often reluctant to alter methods they’ve relied on for years. This resistance is compounded by a cultural preference for maintaining the status quo, summed up in the phrase, “that’s the way things have always been done”.
After discussing all of the issues in the pharmaceutical industry, you might get quite a gloomy picture of the industry’s future. And although these challenges test the companies’ resilience and adaptability, they also offer opportunities for growth and transformation. So let’s explore how decision-makers can ameliorate these obstacles and turn them into stepping stones for progress.
Keeping up with ever-changing regulations can be daunting, but it’s essential to the industry. The key is staying ahead of the curve. Companies can do this by regularly training their teams on the latest guidelines and best practices from agencies like the FDA and EMA. Strong documentation systems and tools like compliance software make it easier to track everything and reduce human error. Pharma marketing can add insult to injury, requiring MLR approval for every new e-Detailer that you make.
Here we can suggest a very actionable solution — an MLR acceleration engine that can proofread your content before you submit it for review, highlighting the risky areas that need attention.
Finding the right talent in pharma is like trying to find a needle in a haystack — especially when everyone’s looking for the same needle. That’s why forward-thinking companies are getting creative, partnering with universities to create specialized training programs. Plus, don’t overlook the talent you already have. Upskilling your current employees and using AI to handle repetitive tasks can help your team focus on the big-picture projects that drive your company forward. Expanding recruitment geographically and networking with potential candidates at industry events are other two solutions that you should keep in mind.
Today, intellectual property protection demands sophisticated strategies. Companies must conduct regular patent landscape assessments and monitor potential infringements proactively. Successful IP management also involves engaging with various stakeholders to balance IP protection with public health considerations, particularly in emerging markets where IP regulations may differ significantly.
Modern supply chains require data-driven optimization and robust security measures. Advanced analytics improve forecasting accuracy and inventory management, while item-level serialization enhances product tracking and reduces counterfeiting risks. Strategic partnerships with third-party logistics providers can also increase your distribution efficiency and allow you to concentrate on core competencies.
As digital transformation accelerates, data security becomes increasingly crucial. A comprehensive cybersecurity framework should include regular risk assessments, employee training programs, and detailed incident response plans. Companies must ensure compliance with data protection regulations while safeguarding sensitive patient information and proprietary research data.
Another effective approach is implementing privileged access (PA), which designates higher access levels to specific files or systems. It enables organizations to secure applications and IT infrastructures, run their business more efficiently, and ensure sensitive data and most critical infrastructure remain confidential. PA can be applied to human and non-human users, such as applications and machines.
The 2020 Cost of a Data Breach Report found that the average total cost of a data breach was significantly higher for the healthcare and pharmaceutical industry compared to less regulated industries such as hospitality, media, and research. Therefore, pharmaceutical companies must have a thorough cyber security policy in place to protect those digital assets.
Building meaningful relationships with healthcare professionals is more important than ever. Digital tools like webinars, virtual meetings, congresses, and web portals make it easier to stay connected. And by actively seeking feedback from HCPs, you can better understand their needs and deliver solutions that truly make a difference. If you’re struggling with HCP and patient engagement, we suggest reading our recent article on healthcare marketing trends that can give you a dose of inspiration.
Change is a good thing when presented the right way. Our job as stewards of the business is to ensure that we make change a more comfortable and incremental process when adopting new technologies. Once we reduce the fear of change, the ability to innovate and adopt will become the culture to ensure technological progress. For example, the immediate reward for adopting something as simple as an electronic logbook can be seen in reductions in overhead, gains in efficient quality reviews, and speeding up batch processing.
Technology must also be presented with a roadmap that allows the entire organization to grasp the benefits that will continue to expand efficiencies and integrate previously disparate data and department processes. Up-front costs for compliance and time spent on system implementation must never drive a decision to move forward with a new solution. The long-term benefits of adopting new technology must be the driving force behind adoption to resolve the technology challenges in the pharmaceutical industry.
Let’s face it — the pharmaceutical industry in 2025 has a lot on its plate. However, these challenges can actually drive innovation and positive change when approached strategically. It’s evident that pharma has enough struggles as it is, so why not simplify one of your processes? At Viseven, we transform your marketing processes to make them more efficient while creating more impactful content. The future belongs to those who can adapt and innovate — and with the right partner by your side, you’re already halfway there.
